Naturally acquired binding-inhibitory antibodies to plasmodium vivax duffy binding protein and clinical immunity to malaria in rural amazonians

Journal of Infectious Diseases

Volumn 214, Issue 10, 2016, Pages 1539-1546

  Nicolete, Vanessa C ^a,b   Frischmann, Sarah ^b   Barbosa, Susana ^a   King, Christopher L ^b,c   Ferreira, Marcelo U ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Amazon; antibodies; Duffy antigen receptor for chemokines; Duffy binding protein; immunity; malaria; Plasmodium vivax

Indexed keywords

DUFFY BINDING PROTEIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIBODY; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DUFFY ANTIGEN BINDING PROTEIN, PLASMODIUM; IMMUNOGLOBULIN G; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ARTICLE; CHILD; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PARASITE PREVALENCE; PARASITE TRANSMISSION; PLASMODIUM VIVAX MALARIA; POPULATION EXPOSURE; PRIORITY JOURNAL; RISK REDUCTION; RURAL AREA; AGED; BLOOD; BRAZIL; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INFANT; MALARIA, VIVAX; MIDDLE AGED; PLASMODIUM VIVAX; PRESCHOOL CHILD; PROSPECTIVE STUDY; RURAL POPULATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BRAZIL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; RURAL POPULATION; YOUNG ADULT;

EID: 85006371030     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw407     Document Type: Article

References (29)

1. Longley RJ, Sattabongkot J, Mueller I. 2016. Insights into the naturally acquired immune response to Plasmodium vivax malaria. Parasitology 2016; 143:154-70.
2. Lin E, Kiniboro B, Gray L, et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 2010; 5:e9047.
3. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 2002; 66: 641-8.
4. da Silva-Nunes M, Codeço CT, Malafronte RS, et al. Malaria on the Amazonian frontier: transmission dynamics, risk factors, spatial distribution, and prospects for control. Am J Trop Med Hyg 2008; 79:624-35.
5. Ladeia-Andrade S, Ferreira MU, de Carvalho ME, Curado I, Coura JR. Age-dependent acquisition of protective immunity to malaria in riverine populations of the Amazon basin of Brazil. Am J Trop Med Hyg 2009; 80:452-9.
6. Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993; 261:1182-4.
7. Zimmerman PA, Ferreira MU, Howes RE, Mercereau-Puijalon O. Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv Parasitol 2013; 81:27-76.
8. Cole-Tobian JL, Michon P, Biasor M, et al. Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect Immun 2009; 77:4009-17.
9. King CL, Michon P, Shakri AR, et al. Naturally acquired Duffy-binding proteinspecific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A 2008; 105:8363-8.
10. Grimberg BT, Udomsangpetch R, Xainli J, et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 2007; 4:e337.
11. Barbosa S, Gozze AB, Lima NF, et al. Epidemiology of disappearing Plasmodium vivax malaria: a case study in rural Amazonia. PLoS Negl Trop Dis 2014; 8:e3109.
12. Gonçalves RM, Scopel KK, Bastos MS, Ferreira MU. Cytokine balance in human malaria: does Plasmodium vivax elicit more inflammatory responses than Plasmodium falciparum?. PLoS One 2012; 7:e44394.
13. Ministry of Health of Brazil. Practical guidelines for malaria therapy [in Portuguese]. Ministry of Health of Brazil, 2010. http://bvsms.saude.gov.br/bvs/publicacoes/guia-pratico-malaria.pdf. Accessed 30 May 2016.
14. Kempinska-Podhorodecka A, Knap O, Drozd A, et al. Analysis for genotyping Duffy blood group in inhabitants of Sudan, the fourth cataract of the Nile. Malar J 2012; 11:115.
15. Singh S, Pandey K, Chattopadhayay R, et al. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein. J Biol Chem 2001; 276:17111-6.
16. Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, et al. B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon. Vaccine 2011; 29:1801-11.
17. Lima-Junior JC, Tran TM, Meyer EV, et al. Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 2008; 26:6645-54.
18. Dent AE, Malhotra I, Wang X, et al. Contrasting patterns of serologic and functional antibody dynamics to Plasmodium falciparum antigens in a Kenyan birth cohort. Clin Vaccine Immunol 2015; 23:104-16.
19. Shakri AR, Rizvi MM, Chitnis CE. Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein region II. J Immunoassay Immunochem 2012; 33:403-13.
20. Sousa TN, Cerávolo IP, Fernandes Fontes CJ, Couto A, Carvalho LH, Brito CF. The pattern of major polymorphisms in the Duffy binding protein ligand domain among Plasmodium vivax isolates from the Brazilian Amazon area. Mol Biochem Parasitol 2006; 146:251-4.
21. Vaida F, Xu R. Proportional hazards model with random effects. Stat Med 2000; 19:3309-24.
22. Batista CL, Barbosa S, da-Silva Bastos M, Viana SA, Ferreira MU. Genetic diversity of Plasmodium vivax over time and space: a community-based study in rural Amazonia. Parasitology 2015; 142:374-84.
23. King CL, Adams JH, Xianli J, et al. Fya/Fyb antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci U S A 2011; 108:20113-8.
24. Ntumngia FB, King CL, Adams JH. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. Int J Parasitol 2012; 42:1055-62.
25. Stanisic DI, Javati S, Kiniboro B, et al. Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl Trop Dis 2013; 7:e2498.
26. Nogueira PA, Alves FP, Fernandez-Becerra C, et al. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun 2006; 74:2726-33.
27. Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-Analysis. BMC Med 2014; 12:150.
28. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between antimerozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-Analysis. PLoS Med 2010; 7:e1000218.
29. Souza-Silva FA, da Silva-Nunes M, Sanchez BA, et al. Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon. Am J Trop Med Hyg 2010; 82:185-93.